• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Cervarix / Singapore Extends HPV Vaccinations From November 1, 2010

Singapore Extends HPV Vaccinations From November 1, 2010

October 5, 2010 By Jonathan Leave a Comment

GovMonitor

Source: Government of Singapore Posted on: 4th October 2010

Medisave was designed to help Singaporeans pay for their hospitalisation expenses.

In recent years, we have liberalised it to help cover some costly vaccinations and the treatment of common chronic diseases at the outpatient level.

In order to preserve the original purpose of Medisave, we limit the withdrawal from Medisave for vaccination and chronic disease management to $300 per Medisave Account per year. We refer to this as Medisave300.

Positive results

Medisave300 has benefitted many Singaporeans. Last year, more than 100,000 patients withdrew more than $23 million from their Medisave accounts under Medisave300.

Outpatient Treatment of Chronic Diseases: Patients with any of the eight common chronic diseases (diabetes, high blood pressure, stroke, lipid disorder, COPD, asthma, schizophrenia and major depression) can use Medisave300 to help pay their outpatient bills.

In 2009, 96,000 patients withdrew $22.5 million under Medisave300 for this purpose. This has reduced their out-of-pocket expenses.

It has also enhanced their health outcomes, as their treatment must follow international best practices to be eligible for claims under this scheme.

Vaccinations: Singaporeans can withdraw under Medisave300 for the Hepatitis B and pneumococcal vaccinations. In the last two months of 2009, 5,570 patients withdrew $755,000 under Mediave300 for this purpose.

Human Papillomavirus vaccination

From Nov 1, Medisave300 will be further extended to cover the vaccination against the Human Papillomavirus (HPV) which causes cervical cancer.

Among Singapore women, cervical cancer is the sixth most frequent cancer and eighth most frequent cause of cancer death.

It is generally treatable when detected early. Most cervical cancer is caused by HPV, but not all.

The Expert Committee for Immunisation (ECI) has reviewed the HPV vaccines and has recommended the inclusion of the HPV vaccines in the National Childhood Immunisation Programme (NCIP) for women aged between 9 and 26 years (age range as recommended by the vaccine manufacturers) as a preventive measure against cervical cancer.

The recommendations were based on the fact that HPV vaccination has been internationally proven to be clinically effective and safe. Each HPV vaccination will require three doses. A/Prof Helen Oh, then Chairperson of the ECI said: “The Committee has reviewed the evidence and recommends HPV vaccination to prevent cervical cancer. However, women who have been vaccinated should still go for regular Pap smears, as vaccine protection is only about 70%.”

School-based immunisation will however not be offered. Instead, we will advise the primary care doctors to raise the ECI recommendation with young female patients and parents with young girls. Immunisation can be done at GPs and polyclinics.

Under the Medisave300 scheme, patients can use up to $300 per Medisave account per year to pay for HPV vaccines.

Patients can use their own Medisave or that of their immediate family members (e.g. parents or spouse) to help pay for the vaccination.

Needy patients with insufficient Medisave balances can seek special financial assistance at the polyclinics.

Related

Filed Under: Cervarix, Gardasil / Silgard Tagged With: cervarix, Cervical Cancer HPV, Gardasil/Silgard, HPV VACCINES, Vaccine Adverse Reactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

UK Families Speak: HPV Vaccines Changed Our Lives

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

the greater good movie trailer

The Greater Good Movie Trailer from BNP Pictures

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in